PDS Biotechnology Co. (NASDAQ:PDSB) Short Interest Update

PDS Biotechnology Co. (NASDAQ:PDSB) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 4,670,000 shares, a growth of 20.7% from the February 13th total of 3,870,000 shares. Based on an average daily volume of 630,100 shares, the days-to-cover ratio is currently 7.4 days. Approximately 13.8% of the shares of the company are sold short.

Analyst Ratings Changes

PDSB has been the subject of a number of research analyst reports. B. Riley lowered their price target on PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a report on Monday, November 25th. HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a research note on Thursday, March 13th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.67.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Marshall Wace LLP increased its holdings in PDS Biotechnology by 38.4% during the 4th quarter. Marshall Wace LLP now owns 39,024 shares of the company’s stock valued at $64,000 after purchasing an additional 10,837 shares during the period. Raymond James Financial Inc. purchased a new position in PDS Biotechnology during the 4th quarter valued at about $26,000. Jane Street Group LLC purchased a new position in PDS Biotechnology during the 4th quarter valued at about $58,000. Blair William & Co. IL increased its holdings in PDS Biotechnology by 29.4% during the 4th quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock valued at $257,000 after purchasing an additional 35,757 shares during the period. Finally, Geode Capital Management LLC increased its holdings in PDS Biotechnology by 9.8% during the 3rd quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock valued at $1,586,000 after purchasing an additional 37,142 shares during the period. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Stock Performance

Shares of PDS Biotechnology stock traded down $0.04 during trading hours on Wednesday, reaching $1.35. The company had a trading volume of 463,266 shares, compared to its average volume of 568,126. The firm has a market cap of $51.56 million, a PE ratio of -1.16 and a beta of 1.68. PDS Biotechnology has a one year low of $1.13 and a one year high of $5.00. The business has a fifty day simple moving average of $1.43 and a 200 day simple moving average of $2.24. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.